Alis Biosciences launches fund to free over USD$30 billion of capital trapped in listed development-stage life sciences and biotech companies
- Significant market inefficiencies have left over USD$30 billion of capital trapped in c.300 listed biotech companies worldwide that have experienced clinical or regulatory setbacks
- Fund provides efficient mechanism to help investors recoup and recycle trapped cash, while allowing residual science and IP to be developed
- Fund to be listed on public markets in due course
- Led by highly experienced industry and investment executives Annalisa Jenkins and Nicholas Johnston
London, UK – 18 April 2025: Alis Biosciences (“Alis”), an investment fund focused on returning capital to investors that is currently trapped in listed, development-stage biotech companies, today formally launches. Founded by highly experienced industry and investment executives, Alis’ goal is to protect public shareholders’ funds while still supporting company management and boards.
